FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119368481> ?p ?o ?g. }

• W3119368481 endingPage "S581" @default.
• W3119368481 startingPage "S581" @default.
• W3119368481 abstract "Abstract Background Patients who are cytomegalovirus (CMV) seropositive (R+) prior to hematopoietic cell transplant (HCT), have 30% incidence of clinically significant CMV reactivation in the absence of prophylaxis. At our institution, letermovir prophylaxis through Day 100 is used in CMV R+ high-risk (HR) (cord blood, haplocord, haploidentical) HCT recipients. We hypothesized that clinically nonsignificant CMV reactivation during letermovir prophylaxis may lead to reconstitution of CMV specific cell mediated immunity (CMV CMI), which may protect the host against CMV disease after letermovir discontinuation. Methods Blood samples from CMV R+ HR HCT recipients on letermovir were tested by dual color CMV specific IL2/IFNg FLUOROSpot pre-transplant and on Days 100, 182 and 360 post-transplant. Clinical and virologic information were obtained from medical records. Results Among 35 participants enrolled to date, 19 were eligible for this analysis, which included only participants with CMV CMI defined as ≥20 spot-forming cells/106 PBMC pre-transplantation and follow up ≥180 post-transplantation. Median age was 51.5 years (range 22-75), 9 were women, 9 were white non-Hispanic, 8 were Hispanic and the most common underlying malignancy was acute myeloid leukemia (n=10). 14 participants had CMV CMI reconstitution at Day 100; including 5 with and 9 without low level CMV DNAemia, defined as &lt;5000 international units/ml in whole blood quantitative polymerase chain reaction assay, while on letermovir prophylaxis. Among the 14 participants, 11 remained free of clinically significant CMV reactivation for a median (range) of 260 (80; 260) days post-letermovir discontinuation, while 3 developed acute graft vs. host disease (aGvHD) followed by clinically significant CMV reactivation. 5 participants did not reconstitute CMV CMI at Day 100 and none of them had DNAemia while on letermovir. 1 of 5 participants without CMV CMI reconstitution or aGvHD developed CMV disease after letermovir discontinuation. Conclusion High-risk patient populations can reconstitute CMV CMI while on letermovir. Ongoing investigation will help establish predictive parameters for CMV CMI that may allow risk stratification for CMV monitoring and letermovir usage. Disclosures Maheen Abidi, MD, Merck (Research Grant or Support) Jonathan Gutman, MD, Merck (Research Grant or Support) Adriana Weinberg, MD, GSK (Grant/Research Support)merck (Grant/Research Support)" @default.
• W3119368481 created "2021-01-18" @default.
• W3119368481 creator A5024868664 @default.
• W3119368481 creator A5041615072 @default.
• W3119368481 creator A5079455826 @default.
• W3119368481 date "2020-10-01" @default.
• W3119368481 modified "2023-09-23" @default.
• W3119368481 title "1102. Reconstitution of CMV-specific cell-mediated immunity during letermovir prophylaxis in hematopoietic stem cell recipients" @default.
• W3119368481 doi "https://doi.org/10.1093/ofid/ofaa439.1288" @default.
• W3119368481 hasPublicationYear "2020" @default.
• W3119368481 type Work @default.
• W3119368481 sameAs 3119368481 @default.
• W3119368481 citedByCount "1" @default.
• W3119368481 countsByYear W31193684812021 @default.
• W3119368481 crossrefType "journal-article" @default.
• W3119368481 hasAuthorship W3119368481A5024868664 @default.
• W3119368481 hasAuthorship W3119368481A5041615072 @default.
• W3119368481 hasAuthorship W3119368481A5079455826 @default.
• W3119368481 hasBestOaLocation W31193684811 @default.
• W3119368481 hasConcept C126322002 @default.
• W3119368481 hasConcept C203014093 @default.
• W3119368481 hasConcept C2776409557 @default.
• W3119368481 hasConcept C2777408962 @default.
• W3119368481 hasConcept C2777732132 @default.
• W3119368481 hasConcept C2778715236 @default.
• W3119368481 hasConcept C2779341262 @default.
• W3119368481 hasConcept C2780727368 @default.
• W3119368481 hasConcept C2911091166 @default.
• W3119368481 hasConcept C3013748606 @default.
• W3119368481 hasConcept C71924100 @default.
• W3119368481 hasConcept C8891405 @default.
• W3119368481 hasConcept C90924648 @default.
• W3119368481 hasConceptScore W3119368481C126322002 @default.
• W3119368481 hasConceptScore W3119368481C203014093 @default.
• W3119368481 hasConceptScore W3119368481C2776409557 @default.
• W3119368481 hasConceptScore W3119368481C2777408962 @default.
• W3119368481 hasConceptScore W3119368481C2777732132 @default.
• W3119368481 hasConceptScore W3119368481C2778715236 @default.
• W3119368481 hasConceptScore W3119368481C2779341262 @default.
• W3119368481 hasConceptScore W3119368481C2780727368 @default.
• W3119368481 hasConceptScore W3119368481C2911091166 @default.
• W3119368481 hasConceptScore W3119368481C3013748606 @default.
• W3119368481 hasConceptScore W3119368481C71924100 @default.
• W3119368481 hasConceptScore W3119368481C8891405 @default.
• W3119368481 hasConceptScore W3119368481C90924648 @default.
• W3119368481 hasIssue "Supplement_1" @default.
• W3119368481 hasLocation W31193684811 @default.
• W3119368481 hasLocation W31193684812 @default.
• W3119368481 hasLocation W31193684813 @default.
• W3119368481 hasOpenAccess W3119368481 @default.
• W3119368481 hasPrimaryLocation W31193684811 @default.
• W3119368481 hasRelatedWork W1994558300 @default.
• W3119368481 hasRelatedWork W1996182916 @default.
• W3119368481 hasRelatedWork W201878797 @default.
• W3119368481 hasRelatedWork W2027173317 @default.
• W3119368481 hasRelatedWork W2103846593 @default.
• W3119368481 hasRelatedWork W2145677053 @default.
• W3119368481 hasRelatedWork W2466043692 @default.
• W3119368481 hasRelatedWork W3029049270 @default.
• W3119368481 hasRelatedWork W3135864954 @default.
• W3119368481 hasRelatedWork W2564805117 @default.
• W3119368481 hasVolume "7" @default.
• W3119368481 isParatext "false" @default.
• W3119368481 isRetracted "false" @default.
• W3119368481 magId "3119368481" @default.
• W3119368481 workType "article" @default.